Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine Announces Pricing of Offering of Common Stock
10:30pm, Wednesday, 20'th Jan 2021
CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of
Beam, SpringWorks Biggest Gainers on BioSpace List
06:14pm, Tuesday, 19'th Jan 2021
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors m
Editas Medicine Announces Offering of Common Stock
04:01pm, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its comm
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
09:47am, Monday, 18'th Jan 2021
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.
Ark Invest Stocks With Big Moves Last Week
07:26am, Saturday, 16'th Jan 2021
Commentary from Ark Invest: We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
06:48pm, Friday, 15'th Jan 2021
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
7 CRISPR Stocks for the Future of Medicine
06:12pm, Friday, 15'th Jan 2021
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on
Despite A 4x Rise, Editas Medicine May Continue To Trend Higher
07:00am, Friday, 15'th Jan 2021
Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments using
3 Healthcare Stocks That Can Double Your Money in 2021
06:20am, Thursday, 14'th Jan 2021
Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
02:18pm, Tuesday, 12'th Jan 2021
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
Why Editas Medicine Stock Is Tumbling Today
12:20pm, Monday, 11'th Jan 2021
One of the biotech's top executives is leaving.
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine
10:00am, Monday, 11'th Jan 2021
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medi
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
06:05am, Monday, 11'th Jan 2021
Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
06:02am, Monday, 11'th Jan 2021
EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle
Editas Medicine Announces Transition of Chief Scientific Officer
06:00am, Monday, 11'th Jan 2021
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D.,
